JFG
SYRE icon

Jefferies Financial Group’s Spyre Therapeutics SYRE Stock Holding History

Jefferies Financial Group’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,388,854
Closed -$23.3M – 2072
2025
Q3 		$23.3M Hold
1,388,854
– – 0.11% 139
2025
Q2 		$20.8M Buy
1,388,854
+140,000
+11% +$2.07M 0.17% 101
2025
Q1 		$20.2M Buy
1,248,854
+31,900
+3% +$664K 0.18% 79
2024
Q4 		$28.3M Buy
1,216,954
+762,147
+168% +$22.3M 0.17% 96
2024
Q3 		$13.4M Buy
454,807
+357,234
+366% +$9.95M 0.1% 132
2024
Q2 		$2.29M Buy
+97,573
New +$3.29M 0.02% 510

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Jefferies Financial Group's SYRE Position: Q4 2025 in Review

Jefferies Financial Group sold out of Spyre Therapeutics (SYRE) in Q4 2025, closing a stake of 1,388,854 shares — an estimated $23.3M sold.

Jefferies Financial Group first reported a position in SYRE in Q2 2024 and held it in 6 quarters. The position peaked at $28.3M in Q4 2024. 153 funds tracked by Wall St. Rank hold SYRE as of Q4 2025.

  • Jefferies Financial Group reported no remaining Spyre Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Jefferies Financial Group sold 1,388,854 Spyre Therapeutics shares in Q4 2025, an estimated $23.3M.
  • Jefferies Financial Group first reported a position in Spyre Therapeutics in Q2 2024 and held it in 6 quarters.
  • Jefferies Financial Group's Spyre Therapeutics position peaked at $28.3M in Q4 2024.
  • 153 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q4 2025.

Based on Jefferies Financial Group's 13F filing for Q4 2025, filed 9 Feb 2026.